Getinge AB
STO:GETI B

Watchlist Manager
Getinge AB Logo
Getinge AB
STO:GETI B
Watchlist
Price: 180.15 SEK 0.92% Market Closed
Market Cap: 49.1B SEK
Have any thoughts about
Getinge AB?
Write Note

Getinge AB
Note Receivable

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Getinge AB
Note Receivable Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Note Receivable CAGR 3Y CAGR 5Y CAGR 10Y
Getinge AB
STO:GETI B
Note Receivable
kr61m
CAGR 3-Years
7%
CAGR 5-Years
-5%
CAGR 10-Years
N/A
Elekta AB (publ)
STO:EKTA B
Note Receivable
kr1B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
Surgical Science Sweden AB
STO:SUS
Note Receivable
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
CellaVision AB
STO:CEVI
Note Receivable
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Arjo AB (publ)
STO:ARJO B
Note Receivable
kr205m
CAGR 3-Years
10%
CAGR 5-Years
21%
CAGR 10-Years
N/A
Sedana Medical AB (publ)
STO:SEDANA
Note Receivable
kr46k
CAGR 3-Years
3%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Getinge AB
Glance View

Market Cap
49.1B SEK
Industry
Health Care

Getinge AB, rooted in the lush landscapes of Sweden, has steadily evolved into a global leader in the medical technology sector. The company began its journey by manufacturing traditional sterilizers over a century ago. Over time, Getinge has carefully navigated and adapted to the ever-changing dynamics of the healthcare industry, positioning itself squarely at the intersection of innovation and practicality. Today, Getinge specializes in a broad spectrum of medical equipment and systems, focusing on critical care, surgery, and infection prevention. This focus is intricately designed to cater to hospitals and healthcare facilities worldwide, ensuring that patients receive the highest standard of care during complex procedures and critical conditions. Revenue streams for Getinge are as diversified as its product portfolio, comprising equipment sales, service contracts, and consumables. The company’s product offerings range from sophisticated ventilators and state-of-the-art heart-lung machines, to efficient sterilization and surgical workflow products. Beyond simply selling devices, Getinge builds sustainable revenue through long-term service agreements and the sale of replacement parts and consumables, which are essential for the ongoing, optimal operation of its technologically advanced machinery. This strategic emphasis on combining cutting-edge product development with a robust support infrastructure underscores Getinge’s business model, ensuring loyalty and ongoing relationships with healthcare institutions globally.

GETI B Intrinsic Value
282.45 SEK
Undervaluation 36%
Intrinsic Value
Price

See Also

What is Getinge AB's Note Receivable?
Note Receivable
61m SEK

Based on the financial report for Dec 31, 2023, Getinge AB's Note Receivable amounts to 61m SEK.

What is Getinge AB's Note Receivable growth rate?
Note Receivable CAGR 5Y
-5%

Over the last year, the Note Receivable growth was 22%. The average annual Note Receivable growth rates for Getinge AB have been 7% over the past three years , -5% over the past five years .

Back to Top